FBR & Co Reaffirms Outperform Rating for Aurinia Pharmaceuticals Inc. (AUPH)
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)‘s stock had its “outperform” rating reissued by analysts at FBR & Co in a note issued to investors on Wednesday. They presently have a $9.00 target price on the stock. FBR & Co’s price objective points to a potential upside of 101.34% from the stock’s current price.
AUPH has been the topic of a number of other reports. Canaccord Genuity restated a “buy” rating and set a $10.00 price target on shares of Aurinia Pharmaceuticals in a research report on Saturday. HC Wainwright lifted their price objective on shares of Aurinia Pharmaceuticals from $7.00 to $10.00 and gave the stock a “buy” rating in a research note on Wednesday, August 17th. Finally, Leerink Swann reaffirmed an “outperform” rating on shares of Aurinia Pharmaceuticals in a research note on Tuesday, August 16th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $7.75.
Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) traded down 1.34% during midday trading on Wednesday, reaching $4.41. 1,006,417 shares of the company were exchanged. The company’s market capitalization is $155.61 million. Aurinia Pharmaceuticals has a 52-week low of $1.42 and a 52-week high of $5.69. The stock’s 50-day moving average price is $2.59 and its 200-day moving average price is $2.80.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/12/fbr-co-reaffirms-outperform-rating-for-aurinia-pharmaceuticals-inc-auph.html
Several hedge funds and other institutional investors have recently added to or reduced their stakes in AUPH. Abingworth LLP increased its position in Aurinia Pharmaceuticals by 479.8% in the second quarter. Abingworth LLP now owns 512,036 shares of the company’s stock valued at $1,388,000 after buying an additional 423,729 shares during the period. Lombard Odier Asset Management USA Corp increased its position in Aurinia Pharmaceuticals by 2.8% in the second quarter. Lombard Odier Asset Management USA Corp now owns 102,294 shares of the company’s stock valued at $283,000 after buying an additional 2,813 shares during the period. Finally, Creative Planning purchased a new position in Aurinia Pharmaceuticals during the third quarter valued at $181,000. 20.04% of the stock is currently owned by institutional investors and hedge funds.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.